Tokuyama (4043) · InitiativeAchieved
Acquisition of JSR’s in vitro diagnostics business and conversion of Tokuyama Life Science into a subsidiary
First written in FY2026-H1. 1 of 4 entries say "Advanced", first in 2026-04-28. Latest entry: FY2026.
4entries
2years
2from disclosures
How it moved
Same theme, other companies
Strengthening the healthcare business through the acquisition of JSR’s in vitro diagnostics business and the conversion of Tokuyama Life Science into a wholly owned subsidiaryA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026AchievedAnnual report
「At a meeting of the Board of Directors dated 22 April 2025, the company resolved to acquire all shares of a new company established by JSR株式会社 and make it a subsidiary, entered into a share transfer agreement on the same date, and acquired the shares on 1 October 2025.」
The acquisition of JSR’s in vitro diagnostic pharmaceuticals and materials business was completed on 1 October 2025. The acquisition consideration was ¥80.637 billion, and the business was made a wholly owned subsidiary under トクヤマライフサイエンス. - FY2026-H1First statedAnnual report
「At a meeting of the Board of Directors dated 22 April 2025, the company resolved to acquire all shares of a new company established by JSR株式会社 and make it a subsidiary, entered into a share transfer agreement on the same date, and acquired the shares on 1 October 2025.」
All shares of JSR-01株式会社, whose corporate name was changed to 株式会社トクヤマライフサイエンス effective 1 October 2025, were acquired and the company was made a wholly owned subsidiary. The acquisition consideration was ¥82.0 billion, and the in vitro diagnostic pharmaceuticals business and related operations have been positioned as core businesses in the healthcare field.